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 Obesity and heart failure are increasingly known as pro-inflammatory states that 
carry a significant and debilitating health burden. High-fat diets represent a common 
pathogenic route to obesity and future development of heart failure. Interleukin-18, a pro-
inflammatory cytokine, has been identified as essential for metabolic and glucose 
homeostasis; however also mediates cardiac dysfunction, in particular diastolic 
dysfunction. A divergence of mouse IL-18KO and IL-18RKO metabolic phenotypes have 
been shown and, additionally, the Na-Cl Co-transporter (NCC) has recently been 
identified as a novel receptor for IL-18. Therefore, we hypothesized that NCC mediates 
the IL-18 induced positive metabolic and negative cardiac effects. Using male C57BL/6J 
mice, we evaluated metabolic and cardiac function changes in wild-type, IL-18KO, and 
NCCKO mice after at least 8 weeks of high saturated-fat and high sugar diet (Western 
Diet, WD). This was accomplished by measurements of body weight gain, fasting 
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glucose, and cardiac systolic and diastolic function parameters. We report NCCKO mice 
had a significantly increased body weight gain compared to baseline vs. wild-type mice 
(55% vs. 22%). Additionally, NCCKO mice had a lower percent worsening from baseline 
in isovolumetric relaxation time (IRT) (29% vs. 123%) and Tei Index (62% vs. 162%) vs. 
wild-type mice (P<0.05). Collectively, the metabolic and cardiac changes in NCCKO mice 
after WD resembled those of IL-18KO mice on the same diet. The Na-Cl Co-transporter 
may function to mediate metabolic and cardiac effects of IL-18 during high-fat diet feeding 
and its possible role in doing so warrants further investigation.
 Introduction: 
 
Obesity: Prevalence, Classification, and Health Risks 
 
 Combinations of poor quality diet, sedentary lifestyle, smoking, and socioeconomic 
status continue to cause and be associated with the frightening prevalence of obesity, 
where 37.7% of adults and 17.2% of youth in the United States were obese (BMI ≥30) in 
2014 (1,2). Although burdened by its limitations in finely discriminating between body fat 
% and lean mass (3,4), body mass index, (BMI, calculated as weight in kilograms divided 
by height in meters squared) for the time being remains the conventional measure used 
in broad population studies to evaluate body composition due to its ease in obtaining and 
reproducibility. Before understanding potential health implications of obesity, it is 
important to define the spectrum of BMI classifications. As indicated in Table 1, the 
calculated value of a patient’s BMI stratifies them into defined groupings where increases 
in BMI are labeled as worsened obesity.  
 
Table 1. BMI classifications 
 
Body Mass Index (BMI) classification 
 
 Underweight Normal Overweight Obese 
Class II 
Obesity 
Class III 
Obesity 
 
kg/m2 <18.5 18.5-24.9 25-29.9 30-34.9 35-39.9 >40 
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Depicted in Figure 1, a J or U-shaped curve exists correlating BMI to risk of 
mortality; where a BMI classification that is either lower than normal or obese carries with 
it an increased risk of all-cause mortality (5, 6). The risk for cardiovascular diseases also 
exhibit similar trends with BMI. When stratified into normal, overweight, or obese BMI it is 
apparent that obesity is associated with higher risk of future development of heart failure. 
In fact, for each 1 increment increase in BMI, the risk of heart failure increases 5% for 
men and 7% for women (7). This evidence clearly places obesity (BMI>30 kgm-2) as a risk 
factor for development of heart failure.  
 
 
 
 
 
      
 
 
 
 
 
 
 
Figure 1. Heart Failure Incidence with Obesity: Adapted from Adams et al, NEJM, 2006. Relationship 
of BMI to relative risk of death compared to the reference group (BMI 23.5-24.9) with respect to age 
groups (A). Adapted from Kenchaiah et al, NEJM, 2002. Increase incidence of heart failure with 
increasing BMI in aging women and men (B).  
A. 
B. 
3 
 
Heart Failure: Definitions, pathophysiology, and paradoxical prognosis with 
obesity  
 
  Normally, the heart and the vasculature are able to adapt and supply adequate 
amounts of oxygenated blood to match increased physiological demands of the body. 
When the heart is unable to supply sufficient oxygenated blood to match systemic needs, 
whether at baseline or during exertion, and symptoms of shortness of breath, dyspnea on 
exertion, fatigue, or exercise intolerance become clinically apparent, a patient is 
diagnosed with the syndrome of heart failure. Echocardiographic assessment of cardiac 
function is essential to evaluating a patient’s status, future prognosis, and tracking of 
medical management. Ejection Fraction (EF, %) is a calculated value derived from the 
difference in volume estimations at end diastole (EDV) and end systole (ESV) of the 
cardiac cycle ([EDV-ESV]/EDV]*100) that is used to evaluate aspects of cardiac 
contractile function. Population based studies have helped establish normal reference 
values for EF where guidelines refer to a normal EF for an adult to be 62% with a 2 
standard-deviation range to be 52-72% (8).  
 While proper contractile function of the heart is undeniably essential, the ability of 
the heart to relax and properly fill (diastole) with blood before the next ejection is just as 
functionally important. The filling capacity of the heart is derived from two processes: 
active re-uptake of intracellular calcium that initiates the relaxation process and the ability 
of myocardium to stretch as one functional unit to accommodate the reception of blood 
from the atria. Impairments in contractility, relaxation, or compliance can lead to a 
decrease in systemic output of oxygenated blood and heart failure.  
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 Essential to a diagnosis of heart failure is the presence of symptoms. After systolic 
and/or diastolic dysfunction manifests symptomatically and an echocardiographic 
assessment has been completed, a patient is grouped into a certain classification of heart 
failure based on ejection fraction. If calculated EF is <40% that patient is diagnosed with 
heart failure with reduced ejection fraction (HFrEF), whereas a patient with calculated EF 
≥50% is diagnosed with heart failure with preserved ejection fraction (HFpEF) (9). 
Additionally, an EF between the two cut-off values (40-49%) places an individual in a 
heart failure with mid-range ejection fraction (HFmrHF); however, this is a novel category 
that is still under investigation (9). The larger divisions of heart failure diagnosis (HFrEF 
vs. HFpEF) both encompass a heart that is unable to meet systemic needs; however, the 
mechanism and etiology of the different diagnosis are mixed, with some features common 
to both, and others that predominate in one or the other.  
Whereas an ischemic insult results in an intense local immune response that 
extends myocyte loss, ventricular chamber dilation, and systolic impairment (classic of 
HFrEF), the consequence of comorbidities as T2D, obesity, and a poor-quality diet that 
result in a low grade state of inflammation contribute to ventricular hypertrophy, stiffness, 
increased filling pressures, overt diastolic dysfunction and a restricted/hypertrophied 
ventricular cavity (more classic of HFpEF, Figure 2) (32,33). Despite the differing original 
insult to the myocardium, a common feature of both heart failure classifications is 
supranormal inflammation that alters cardiac structure and function in one form or 
another. Thus, greater understanding of the intricate biology of inflammation within the 
context of metabolic and cardiac dysfunction is essential. 
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Figure 2. Differing cardiac insults lead to a spectrum of geometric and functional changes. 
Progression of cardiac structure and function based on differing initial insults. Acute ischemic damage 
(right) causes rapid and widespread myocyte cell death that sparks an intense local immune response. 
Secondary loss of nearby functional myocytes due to immune activation amplifies local damage. Ventricular 
volume increases in a Frank-Starling mechanism to increase preload to compensate for poor contractility, 
culminating in dilated LV and systolic dysfunction. Chronic systemic inflammation stemming from 
multifactorial combinations of aging, poor quality diet, obesity, and Type II Diabetes (T2D) (left) can cause 
myocyte hypertrophy and stiffness that restrict the ventricle’s ability to relax and reduce ventricular tissue 
compliance resulting diastolic dysfunction.     
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Epidemiologic studies to estimate new and total cases of a disease on a population 
scale serve to evaluate disease burden placed on the collective health care system and 
members. A recent population study evaluating the decade of 2000—2010 discovered a 
decline in incidence of overall heart failure diagnosis; however a categorical shift in 
incidences occurred. HFrEF reduced to a greater degree than HFpEF to the point that 
HFpEF is making up a larger proportion of new heart failure cases (10, 11). Problematic to 
this rise in HFpEF is the nearly matching high mortality rate at 5 years with HFrEF (65% 
vs. 68% respectively), and the disconnect that current therapeutic options for HFrEF 
patients do not appear to improve mortality in HFpEF patients (12,13). Perhaps due to the 
multifactorial nature of heart failure including aging, obesity, and hypertension that are 
exhibiting parallel prevalence increases, the overall prevalence of heart failure continues 
to rise in the United States (11).   
 Although established that obesity increases the risk of developing heart failure, 
after the onset of heart failure there in fact may be a survival benefit associated with being 
obese. Depicted in Figure 3, multiple studies have replicated this paradoxical finding of 
lowest mortality in heart failure patients to be patients that are obese (BMI 30-34.9 kg/m2) 
(14–18). This apparent relationship is complex, but some varying hypothesis exist in 
attempts to explain this phenomenon including: a metabolic “reserve” that benefits obese 
patients during the catabolic state of heart failure, increased skeletal muscle mass, 
increased levels of adipocyte derived anti-inflammatory/insulin-sensitizing proteins (19),  
decreased sympathetic nervous system activation (20), or earlier identification of disease 
and better tolerance of protective medications (21). Interestingly, the paradox appears to 
be more apparent in patients with low cardiorespiratory fitness, with low CRF obese 
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patients again having improved survival over low CRF normal BMI patients (22). Although 
unclear, the biological mechanisms that contribute to outcomes in patients with co-
existing metabolic and cardiac dysfunction certainly warrant further investigation.    
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mortality in Obese HF patients. Adapted from Horwich et al JACC 2001, Curtis et al JAMA 
2005, and Oreopoulos et al AHJ 2008. Differing representations of improved survival in obese (BMI ≥ 
30kg/m2) patients that have diagnosed heart failure.  
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Inflammation: obesity derived and heart failure mediator 
 
The numerous adverse effects of obesity for development of morbid conditions 
including Type II Diabetes (T2D), coronary artery disease, heart failure, cancer, and more 
have been noted for decades. Elucidation of exact chronologic events that initiate a path 
toward obesity and end with a co-morbid condition have been elusive, but our 
understanding of changes in physiology during obesity have expanded.  
The overlap of metabolic and immune system functions to homeostasis indicate 
that perturbations of one can have a maladaptive domino effect on the other. Individual 
observations in the clinic and within entire populations have depicted a clear connection 
between metabolic dysfunction and immune responses. Increases of BMI (overweight 
and obese) in men and women are positively associated with increased levels of high-
sensitivity C-Reactive Protein (hs-CRP), a protein secreted by the liver in response to 
stress or injury that functions to augment acute innate immune activity (23). These 
observations have led to the catch-phrase describing obesity as a state of “low-grade 
chronic inflammation.”   
When the balance of energy intake exceeds energy expenditure, due to any 
combination of increased whole caloric consumption, increased dietary energy density 
from higher saturated fat composition, or decreased physical activity, the capacity of 
adipose tissue to store the energy is exceeded. Due to the fact that adipose tissue is 
composed of a mix of adipocytes, networks of endothelial and smooth muscle cells, and 
resident macrophages and T-cells, changes in the integrity of adipocytes are rapidly 
sensed and transmitted systemically (24). Overwhelming the adipose storage depot leads 
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to a detrimental cycle of adipocyte dysfunction and immune activation with whole body 
negative implications.  
Depicted in Figure 4, multiple hypothesis exist for how adipocyte dysfunction 
manifests with subsequent immune activation and eventual metabolic dysfunction. 
Included are synergistic activity of adipocyte-derived cytokines, free fatty acid (FFA) 
release, endoplasmic reticulum (ER) and oxidative stress, and hypoxia from outgrowing 
local vascular supply (25). Prolonged adipocyte and immune cell shifts toward pro-
inflammatory routes participate in local and systemic impairment of insulin sensitivity and 
glucose utilization, hallmarks of T2D and metabolic syndrome (26).  
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Figure 4. Inflammation from adipocytes. (Top) Adapted from Heredia et al Proceedings of the Nutrition 
Society 2012, Mechanisms for how adipocyte dysfunction communicates with local macrophages to 
perpetuate a state of inflammation that lead to insulin resistance. (Bottom) Adapted from Ouchi et al 
Nature Reviews: Immunology 2011, Development of obesity changes adipose tissue morphology and 
composition toward a milieu of pro-inflammatory cytokines and adipokines that derail homeostatic 
metabolism.  
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 After growing evidence of increased cytokines such as TNF-α, IL-6, and other 
inflammatory components such as hs-CRP directly associated with increased heart failure 
incidence and worsening heart failure functional classification, it became apparent that 
the presence of inflammation in heart failure patients could be valuable targets to predict 
outcomes (27–29). Basic science observations of cytokines, such as TNF-α, IL-1β, and IL-
18, causing ventricular remodeling, myocyte hypertrophy, decreasing contractility,  and 
inducing apoptosis pushed the role of inflammation from association toward causative in 
the pathogenesis of heart failure (30–33). Discussed further is a major component of 
inflammation, Interleukin-18, and its contributions to immune, cardiovascular and 
metabolic function.   
 
 
IL-18: Production and Signaling 
 
Since first implicated in 1989 as a soluble factor that, in combination with IL-12, 
induced Interferon-γ in a mouse model of endotoxemia, our understandings of the 
signaling and function of Interleukin-18 in human physiology and pathophysiology have 
expanded (34). The Interleukin-1 family of cytokines, now encompassing 11 proteins of 
varying homology including IL-1β and IL-18, have been extensively studied for how they 
contribute to coordination of immune response. Unlike its IL-1 family member IL-1β, the 
human chromosome 11 and murine chromosome 9 gene product IL-18 has been 
identified to be constitutively expressed in human peripheral blood mononuclear cells 
(PBMCs, including T cells, B cells, natural killer (NK) cells and monocytes) as well as 
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endothelial cells, keratinocytes, osteoblasts, dendritic cells, astrocytes, microglia and gut 
epithelial cells (35,36). Depicted in Figure 5, The 24kD 193 amino acid product is 
synthesized without an endoplasmic reticulum signaling peptide, does not contain N-
glycosylation sites, and remains inactive in the cytosol until cleavage by the cysteine 
protease Caspase-1 creates the 17kD 157 amino acid active form to be secreted out of 
the cell via plasma membrane pore or released by membrane rupture (37–40). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. IL-18 Activation and Release. Activation of an Inflammasome yields an active Caspase-1 that 
is able to cleave Pro-IL-18 into its active form, IL-18. Secretion out of the cell is mediated by either 
release out of an intact cell membrane through a pore (shown here), or via cell membrane rupture, as 
during cell death.  
IL-18 
IL-18 
IL-18 
Activated  
Inflammasome  
& Caspase-1 
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While constitutive synthesis exists in the aforementioned cells, synthesis of IL-18 
induced by stimuli is partially controlled by the transcription factor Nuclear Factor kappa-
light-chain-enhancer of activated B cells, commonly NF-κB (41). Naturally then, a wide 
array of stimuli that converge upon the activation of NF-κB, including microbial and 
endogenous products binding to the Toll-like receptor (TLR) family, cytokines, and the 
antigen receptors T-cell Receptor (TCR) and B-cell Receptor (BCR), result in an increase 
in IL-18 production. Of note, the kinetics of IL-18 induction after TLR stimulation are 
different from IL-1β. Lipopolysaccharide (LPS) activation of TLR4 showed IL-18 levels 
reach maximal level at 8 hours and remain elevated at 24 hours, whereas IL-1β reaches 
maximum levels at 4 hours and decrease by 24 hours (42).  
Once produced, activated, and secreted, IL-18 diffuses locally and is capable of 
acting in autocrine, paracrine, and endocrine fashions. With resemblance to IL-1β 
signaling, a heterodimeric receptor complex mediates conversion of the extracellular IL-
18 signal to an intracellular response(43). Depicted in Figure 6 below, the two proteins that 
complement each other to facilitate binding and signal transduction are IL-18Rα and IL-
18Rβ. The alpha chain is expressed on a broad array of cell types, possess low affinity 
for IL-18, and alone is non-responsive to IL-18 in vitro (43–45). In contrast, the beta chain, 
known also as an accessory protein, is expressed in lung, spleen, prostate, small 
intestine, peripheral blood T cells and NK cells and has higher affinity for its IL-18 
substrate (45). Alone, each receptor is unable to activate NF-κB or c-Jun N-terminal kinase 
1 (JNK1, a regulatory protein for gene transcription); however, in combination the 
receptors elicit strong NF-κB and JNK1 activation (45). Additional intricacies of the IL-18 
receptor complex, responsible for the research here, are discussed later.  
14 
 
Due to partial cytoplasmic homology of the IL-1 and IL-18 receptors, it is no 
surprise the two provoke a similar intracellular response (43). Intracellular cascades 
consist of myeloid differentiation primary response 88 (MyD88) recruitment to the receptor 
tail, IL-1 Receptor-Associated Kinase (IRAK) and TNF receptor associated factor 6 
(TRAF6) interaction, and eventual NF-κB activation (46–48). Distinct again from IL-1 
signaling is the additional activation of mitogen-activated protein kinase (MAPK) and 
signal transducer and activator of transcription 3 (STAT3) with IL-18 stimulus as 
evidenced by in vitro studies of NK cell lines (49). 
Also integral to net IL-18 signaling are the soluble circulating endogenous protein 
isoforms, known as IL-18 Binding Protein (IL-18BP), that bind free extracellular IL-18 in a 
1:1 ratio and remove it from the pool of available and functional IL-18 (50). Constitutively 
secreted at levels approximately 20 times that of IL-18 and with high affinity for IL-18, IL-
18BP functions seemingly as a natural balance to the activation of the T helper cell 
response to prevent a detrimental autoimmune cycle (51–53). 
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Figure 6. IL-18 Binding and Signaling. Once in the extracellular space, free and active IL-18 (not bound 
to circulating IL-18BP) binds to its receptor complex composed of, at least, IL-18Rα and IL-18Rβ. 
Activation of the receptor complex leads to intracellular cascades including the activation of MyD88, 
IRAK4, TRAF6, JNK, MAPK, STAT3, and NF-κB, which facilitate transcription of genes involved in 
numerous cell functions, including inflammation.  
β α IL-18 
IκB NF 
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IRAK4 
TRAF6 
MyD88 
JNK1 
MAPK 
STAT3 
IL-18 
IL-18BP 
Pro-inflammatory 
Gene transcription 
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IL-18: Functions  
 
Role of IL-18 in the Immune System 
 
The uniqueness and complexity of IL-18 biology is derived from its pleotropic 
effects on multiple cells and organ systems as well as the intricate balance between 
homeostatic and pathologic functions. In regards to the immune system, IL-18 has its 
hand in innate, adaptive, and autoimmunity; responsible for activation and/or 
differentiation of multiple cell types including macrophages, naive T cells, NK cells, and 
B cells (54). Specific cytokine environments coordinate and specialize immune cell 
responses and contribute to acute disease states (such as myocardial infarction, 
microbial invasion of the gut, and skin lesions), chronic disease states (such as heart 
failure and Type II diabetes mellitus) and genetic mutations (macrophage activation 
syndrome) (54–56).  
Inflammation is an evolutionarily refined process initiated by the immune system 
designed to clear local and global pathogen or damage insults and best attempt to restore 
tissue to its previous functional state. The ability of IL-18 to induce chemokine production 
to attract neutrophils (57), increase endothelial Intercellular Adhesion Molecule-1 (ICAM-
1), Vascular Cell Adhesion Molecule-1 (VCAM-1), and E-Selection expression (58, 59), and 
stimulate production of IL-6 and IL-1β place it central to initiation and propagation of 
inflammation in various disease states (60). Innate immune cell products, such as IL-18, 
serve also to bridge the innate and adaptive immune responses. Pathogen associated 
molecular patterns (PAMPs), such as lipopolysaccharide or bacterial DNA, or damage 
associated molecular patterns (DAMPs), such as extracellular ATP or mitochondrial DNA, 
17 
 
bind to a family of pattern recognition receptors (PRRs) that include the Toll-Like 
Receptors (TLRs). Binding of ligands to TLRs present on neutrophils and macrophages 
initiates intracellular cascades leading to production of cytokines, including IL-18. 
Interleukin-12 importantly acts to increase plasma membrane IL-18Rα levels in CD4+ T 
cells, rendering the naïve T-cells able to bind extracellular IL-18. Binding of Il-18 to the 
IL-18 receptor complex and subsequent intracellular cascades culminate in transcription, 
translation, and release of INF-γ from the T-cell (61). IL-18 induced release of INF-γ further 
results in activation of macrophages to begin a pro-inflammatory feedback mechanism to 
amplify IL-18, IL-1β, and TNF-α levels, the defining characteristics of the Th1 response 
(62).  
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Role of IL-18 in the cardiovascular system: Health and Disease 
 
 Little evidence exists for the function of IL-18 in homeostasis and preservation of 
the myocardium or vasculature. The identification of pro-inflammatory cytokines, 
including IL-18, as factors associated with diseases such as hypertension, 
atherosclerosis, myocardial infarction, and heart failure has been studied extensively in 
the clinical and pre-clinical realms. 
 
Hypertension  
 
Hypertension is now present in approximately 46% of U.S. adults with varying 
etiologies (63). In response to prolonged hypertension, the myocardium undergoes 
physiologic hypertrophy to decrease wall stress and oxygen consumption in order to 
continue ejecting adequate volumes of blood without entering into an ischemic state (64). 
However, sustained pressure overload tips the physiologic hypertrophic adaptation to 
pathologic as further hypertrophy stiffens the ventricle, impairs coronary circulation, and 
can lead to arrhythmias. Evidence of this hypertrophy discovered on electrocardiographic 
or echocardiographic assessment is an independent risk factor for future cardiovascular 
morbidity and all-cause mortality (65–67).  
Clinical correlations and basic science investigation have identified IL-18 to be 
involved in the hypertrophic response (Figure 7, below). In patients, increased circulating 
IL-18 is correlated with hypertension as well as left ventricle mass (68). In a mouse model 
of pressure overload induced by thoracic aorta constriction (TAC), the genetic deletion of 
IL-18 (IL-18KO) resulted in less hypertrophy than wild-type control; however, was 
accompanied by worse LV contractility, indicating that in response to pressure overload 
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IL-18 is necessary to some degree for hypertrophic adaptations (69). A molecular pathway 
identified in hypertrophy induced by IL-18 is the PI3K→Akt→GATA4 signal that leads to 
transcription of genes including atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP), and β-myosin heavy chain (MHC), presumably to combat pressure overload (70, 
71). In vitro, cyclical mechanical stress of cardiomyocytes increases mature IL-18 that is 
blunted with neutralizing antibodies or IL-18BP while in vivo, pressure overload increased 
myocardial IL-18 mRNA and protein, but decreased IL-18BP mRNA and protein (71). To 
further support the notion of IL-18 directly involved in the hypertrophic response, daily 
administration of IL-18 to young healthy mice induced left ventricular wall thickness and 
diastolic dysfunction (72,73). The expanding understanding of IL-18 in mediating 
hypertensive induced cardiac remodeling places further investigation of IL-18 signaling at 
the forefront of cardiovascular research.  
 
 
 
 
 
 
 
Figure 7. Hypertrophic Adaptation and IL-18. IL-18 is capable of signaling cascades leading to 
physiologic hypertrophy and diuresis to adapt to elevated afterload. Sustained hypertrophy; however, 
impairs ventricular function and increases mortality risk.  
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Atherosclerosis 
 
Atherosclerosis is increasingly defined as an inflammatory disease. Disease 
progression is characterized by damaged endothelium, due to shear stress 
(hypertension), oxidative stress from increased lipid metabolism (hyperlipidemia) or 
cholesterol accumulation (hypercholesterolemia), that attracts neutrophils to hone and  
activate macrophages and T lymphocytes that amplify local inflammation resulting in 
advanced complicated lesions in vessel walls (74,75). IL-18 has an integral role in gradual 
progression of lesions as well as the latter stages of plaque instability and rupture (Figure 
8, below). Endothelium that has accumulated low-density lipoproteins and its derivatives 
are prone to oxidative stress and release of cytokines. IL-18 induced increases in 
adhesion molecules (ICAM-1) on the plasma membrane of the endothelium promote 
monocyte and T-cell adhesion and extravasation into the vascular intima where lipids are 
accumulating.  
The aforementioned combination of local IL-12 and IL-18 drive the differentiation 
of naïve T-cells into the Th-1 phenotype to produce INF-γ within the vascular intima. 
Macrophage activation via INF-γ polarizes that cell line to a pro-inflammatory state, 
deemed the M1 response. Macrophages become significant local effector cells 
contributing to smooth muscle cell proliferation, necrosis of the plaque core, and extra-
cellular matrix breakdown (76). Unstable/symptomatic plaques have shown increased 
levels of IL-18mRNA compared to stable/asymptomatic plaques in patients (77). Inhibition 
of IL-18 with an IL-18BP expression plasmid decreased lipid deposition, macrophage and 
T-lymphocyte infiltration, and increased collagen content in mice, further indicating that 
IL-18 is involved in plaque development and stability (77,78).  
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Figure 8. Atherosclerosis and IL-18. Initial LDL and lipid accumulation within the vascular intimal wall 
occurs over a prolonged period. Extended exposure of endothelial cells to lipids results in oxidative 
stress, endothelial damage, and initiation of pro-inflammatory cascades, including IL-18, which recruits 
immune cells to the damage site. Local inflammation is amplified and leads to cell death within the plaque 
core and proliferation of surrounding smooth muscle cells that further narrow the vessel. Exacerbation 
past this point can create symptomatic ischemia with exercise or at rest.  
Accumulation of lipids 
in intimal wall 
• Oxidative stress 
damages 
endothelium which 
releases IL-18 
• IL-18 causes 
leukocyte, 
monocyte, and T-
cell attraction and 
adhesion 
• IL-18 contributes to a  
pro-inflammatory cycle  
that leads to plaque 
expansion, necrosis, and 
instability 
22 
 
Myocardial Infarction 
 
After plaque rupture, coronary vessel occlusion, and myocardial ischemia, the 
crosstalk between immune cells and surviving myocytes and fibroblasts is essential to 
best repair the cardiac tissue. While essential to a degree, prolonged and exaggeration 
of this response is detrimental as it continues to destruction of remaining cardiomyocytes, 
expands infarct size, and accelerates the progression to heart failure (79). If the immune 
system response teeters the myocardium on the delicate balance between repair and 
worsening prognosis, it comes logically that suppression of an exaggerated immune 
response could be beneficial (80). While IL-1β has received more investigation and 
therapeutic attention in this setting, IL-18 is also a key player.  
After ischemia reperfusion in the mouse, cardiac, endothelial, and smooth muscle 
cell IL-18 mRNA is increased, as well as serum IL-18 levels (81,82). Pre-treatment with an 
IL-18 neutralizing antibody or injection of mesenchymal stem cells overexpressing IL-
18BP into the coronary artery of mice reduced infarct size and improved ejection fraction 
(82,83).  The cardiodepressant effects of IL-1β have been shown to be mediated by 
induction of IL-18, as IL-18KO mice treated with IL-1β did not have reduced fractional 
shortening compared to wild-type mice treated with IL-1β (32). Therefore, where treatment 
with IL-1R blockade improves cardiovascular outcomes in patients with previous 
myocardial infarction (MI), and IL-1 effects are in part mediated by IL-18, it is possible 
that inhibition of IL-18, either with exogenous binding protein or neutralizing antibody, 
could also be a treatment that yields meaningful clinical benefits to patients who achieved 
reperfusion after MI (84).  
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Heart Failure 
 
Regardless of etiology, a staple of a failing heart is damaged or stressed 
myocardium that recruits and activates effector immune cells (79). Cytokine signaling 
between immune, fibroblast, endothelial, and cardiac cells induces altered calcium signal 
coordination, oxygen free radical damage, apoptosis, and myofibroblast expansion that 
combine to impair systolic and/or diastolic function and manifest as clinically relevant 
symptoms (85).  
Clinical and basic science observations have identified elevated IL-18 to be 
associated with worsening heart failure functional class and involved in the pro-fibrotic 
response that contributes to diastolic dysfunction (86, 87). Carbone et. al. have shown that 
IL-18KO mice on a high-saturated fat diet have preserved diastolic function despite 
greater obesity (86). In a rat model of metabolic syndrome and IL-18 overexpression, 
worsened diastolic dysfunction but preserved ejection fraction was noted (88). 
A classic characteristic of heart failure is over activation of the sympathetic nervous 
system (SNS) that attempts to compensate for a failing heart’s inability to perfuse tissue 
as it once could. The interplay between sympathetic activation and ensuing immune 
activation that perpetuates a failing heart, specifically involving IL-18, has been 
investigated in humans and mice (Figure 9, below). After noting an association between 
increased serum norepinephrine and IL-18 in patients with non-ST-segment elevation 
myocardial infarction (NSTEMI) or unstable angina, Xiao et. al. observed that acute over-
activation of β-AR receptors with isoproterenol in mice induced myocardial IL-18 and 
macrophage infiltration (89). Blockade of IL-18 using antibodies reduced chemokine, 
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adhesion molecule, and pro-inflammatory cytokine gene expression, as well as reduced 
cardiac inflammation, fibrosis, and improved functional parameters (89).  
Additionally involved in the circulatory system’s response to heart failure is 
activation of the renin-angiotensin-aldosterone system (RAAS), again in attempt to 
maintain cardiac output by retaining Na+ and arterial vasoconstriction. There is increasing 
evidence of hormonal (Angiotensin II) and inflammatory (IL-18) convergence onto 
pathways causative of diastolic dysfunction. Angiotensin II increases myocardial fibrosis 
in mice, partially through production of Osteopontin (OPN). OPN is a protein secreted by 
macrophages, fibroblasts, and myocytes into the extracellular space that is critical to 
collagen synthesis and deposition, as well as myofibroblast differentiation (90). IL-18 
administration to mice has also been shown to increase OPN levels, along with 
myocardial fibrosis, collagen, and ventricular stiffness (Figure 9, below) (91).  
In summary, basic science models and patient cohorts have represented IL-18 
involvement in development and worsening of cardiovascular diseases including 
hypertension, atherosclerosis, myocardial infarction, and heart failure. Further 
clarification of IL-18 pathways may pay great dividends going forward for patients at risk 
for and those who have already developed the aforementioned diseases.  
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Figure 9. IL-18 and diastolic dysfunction. Overexpression of IL-18 and induction of the protein 
Osteopontin (OPN) leads to fibrosis and diastolic, while genetic knockout of IL-18 in a model of diet-induced 
obesity preserved diastolic function and reduced fibrosis (80). Stimulation of β-Adrenergic receptors with 
isoproterenol induces immune cell recruitment and diastolic dysfunction that was preserved with antibody 
blockade of Il-18 (82).   
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Role of IL-18 in metabolism: Health and Disease 
 
The complicated nature of IL-18 signaling in metabolism is in part due to 
contrasting physiological observations. In the early 2000’s, clinical correlations between 
circulating IL-18 levels and obese and diabetic patients were made. Compared to healthy 
volunteers, patients with type 2 diabetes mellitus had higher serum IL-18 (92). Obese 
women were also found to have higher serum IL-18 levels that positively correlated with 
BMI, waist-to-hip ratios, and negatively correlated with insulin sensitivity (93). Acute 
hyperglycemia in healthy and glucose intolerant patients showed an increase in IL-18 
levels that was prolonged in patients with impaired glucose tolerance (94). A separate 
study incorporating a large community population indicated a consistent graded 
relationship between plasma IL-18 and odds ratio for metabolic syndrome (95).  
This discovery of IL-18 positively correlating with the metabolic syndrome in 
patients has led to a growing number of preclinical investigations. Early evaluation by 
Netea et. al. in IL-18KO mice showed the spontaneous development of obesity and insulin 
resistance at 6 months of age that was preceded by increased chow intake (hyperphagia) 
(96). Supporting data by Zorrilla et. al. again showed that IL-18KO mice developed a 
phenotype of increased body weight and adiposity preceded by increased standard chow 
or high fat diet intake, as well as an increased respiratory exchange ratio (RER) (97,98). 
Collectively, these initial results indicated that although clinical data suggested a 
pathophysiologic association of IL-18 in the development of the metabolic syndrome, the 
genetic absence of IL-18 was also able to produce a phenotype of obesity and insulin 
resistance.  
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Recent work has further implied IL-18 to be essential to body weight and glucose 
homeostasis through catalytic activation by the NLRP1 inflammasome in the mouse. 
Collectively, Murphy et.al. was able to show NLRP1’s ability to respond to energy intake 
and coordinate metabolic homeostasis, specifically through IL-18 (99).  
Interestingly, administration of recombinant IL-18 (rIL-18) to mice via intravenous 
administration had no effect on food intake while intracerebral administration significantly 
reduced food intake, suggesting the effect of IL-18 on food intake may occur within the 
central nervous system (CNS) (96,98). After elegant work discovered precise neurocircuit 
elements responsible for feeding behavior in the lateral hypothalamus (LH), the central 
effects of IL-18 on appetite were further investigated (100,101). It was discovered that IL-18 
altered neuron activity in the (LH) to result in decreased food intake in mice (101). 
Peripherally, IL-18 administration to mice has been shown to slightly increase 
insulin sensitivity, increase 5’ AMP-activated protein kinase (AMPK), and increase fatty 
acid oxidation (96,102). Additionally, rIL-18 administration to mice decreased body weight 
and improved lipid handling capacity of the liver (103). Thus, an overall divide of IL-18 
metabolic contributions between the CNS to regulate food intake and the periphery to 
positively alter insulin sensitivity and lipid metabolism has been discovered (Figure 12).  
The apparent negative contributions of IL-18 to cardiovascular disease mixed with 
possible positive influences on metabolism, namely decreased food intake and improved 
glucose/lipid metabolism, create an unclear therapeutic potential of IL-18. On one hand, 
inhibition of IL-18 signaling at the myocardium appears beneficial, as it has been shown 
to attenuate cardiac dysfunction. However, genetic absence of IL-18 in mice leads to overt 
obesity and T2D. Thus, an apparent disconnect in IL-18 signaling exists (Figure 12).  
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Similarities and differences in IL-18KO and IL-18RαKO mouse phenotypes: A role 
for the Na-Cl Co-transporter? 
 
As discussed before, deletion of the ligand IL-18 (IL-18KO) results in a phenotype 
of obesity and T2D (96,98). However, mildly differing phenotype results have been 
observed after the genetic deletion of the IL-18Rα, responsible for binding IL-18. IL-
18RαKO mice display hyperinsulinemia and decreased glucose tolerance akin to IL-18KO 
mice; however, regardless of diet, they exhibit body weight changes and food intake 
levels that resemble wild-type mice more than IL-18KO mice (Figure 10) (102, 104).  
 
 
 
 
 
 
 
 
 
Figure 10. IL-18KO and IL-18RKO divergence. Adapted from Lindegaard et al Diabetes 2013 and 
Pazos et al Scientific Reports 2015. (Top) Body weight gain on either standard diet (SD, CH, chow) or 
high-fat diet (HFD) of wild-type, IL-18RαKO, or IL-18KO mice. Apparent is the trend that IL-18RαKO mice 
do not have a growth pattern that is alike IL-18KO mice. (Bottom) Chow or HFD food intake of wild-type, 
IL-18RαKO, or IL-18KO mice. Again, the IL-18RαKO mice do not exhibit hyerphagia like IL-18KO mice.  
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Additionally, peripheral disconnects in IL-18 signaling have been shown in the 
context of atherosclerosis. In a mouse model of atherosclerosis, IL-18RαKO was unable 
to decrease plaque size in vivo or prevent IL-18 binding to isolated endothelial cells ex 
vivo. A cell surface binding alternative for IL-18 was found to be the 125 kDa Na-Cl Co-
transporter (NCC) (105). The distal convoluted tubule (DCT) apical transmembrane protein 
is known to be responsible for ~5% of Na+ reabsorption in the kidney and is the target for 
thiazide-type diuretics that are considered to be part of first-line therapy for hypertensive 
patients (106,107).  
Further investigation yielded that IL-18 had strong binding affinity for NCC, and IL-
18 treatment in vitro to cells expressing NCC and not IL-18Rα increased protein tyrosine 
phosphorylation, indicating a signal is transduces across the plasma membrane due to 
IL-18 binding to NCC. Genetic changes in the mouse model of atherosclerosis yielded 
further support to in vitro IL-18/NCC communication observations. Decreases in 
atherosclerotic lesion are were only observed in the double knockout of Apoe−/−NCC−/−IL-
18Rα−/− and not in Apoe−/−NCC−/− or Apoe−/−IL-18Rα−/− backgrounds (Figure 11, below). 
Combined, these results indicated that the membrane localized Na-Cl Co-transporter 
effectively played a role in mediating atherosclerosis through IL-18 signaling in the 
mouse, suggesting that NCC may also mediate other physiologic processes where IL-18 
signaling is important, possibly including metabolic and cardiac function discussed 
previously.  
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Figure 11. NCC in Atherosclerosis. Adapted from Wang et al Nature Medicine 2015, Aortic root lesion 
intima area in different genetic backgrounds. Where Apoe−/−NCC−/− or Apoe−/−IL-18Rα−/− 
backgrounds are not protected from atherosclerosis, Apoe−/−NCC−/−IL-18Rα−/− significantly decreases 
aortic lesion area intimal area. These results implicate NCC as a receptor in physiologic processes where 
IL-18 activity is involved.  
 
 
Thus, further understanding the mechanism by which IL-18 signaling is achieved 
may reveal intricacies to its biology, role in homeostasis, and metabolic and cardiac 
disease as well as open therapeutic doors (Figure 12, below). The major goal of the work 
presented here, and still underway, is aimed at unraveling the role of NCC as a co-
receptor for IL-18 signaling in metabolic and cardiac function by investigating the genetic 
knockout of NCC in a mouse model of high-fat diet induced obesity.  
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Figure 12. IL-18 Physiology. The complex interplay of IL-18 and its contributions to immune, 
cardiovascular, and metabolic function. Within the immune system, IL-18 mediates communication 
between cell types to specialize the immune response toward a pro-inflammatory state. In the vascular 
system, IL-18 functions between endothelial, macrophages, and T-cells to promote atherosclerosis. 
Within the heart, IL-18 can induce cardiomyocyte hypertrophy and fibroblast collagen deposition that 
contribute to diastolic dysfunction. The effects of IL-18 on metabolism are less clear-cut, but include 
decrease food intake within central nervous system and possible positive modulation of glucose and lipid 
metabolism in the periphery at adipose and skeletal muscle tissue. The role of NCC as a receptor that 
mediates these functions is investigated here.  
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 With the comprehensive background of Interleukin-18 being required for 
metabolic homeostasis, but able to cause ventricular hypertrophy, fibrosis, and 
dysfunction with the capability to act through its co-receptor Na-Cl Co-transporter (NCC) 
to elicit function; we hypothesize NCC may act to mediate IL-18 effects on metabolic 
and cardiac function. Therefore, the genetic knockout of NCC (NCCKO) will worsen the 
metabolic phenotype, but attenuate the cardiac phenotype after western diet feeding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Hypothesis Schematic. 
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Methods 
 
a. Animals 
 
i. All animal experiments were conducted under guidelines on the humane 
use and care of laboratory animals for biomedical research published by 
the National Institutes of Health. The Institutional Animal Care and Use 
Committee (IACUC) of Virginia Commonwealth University approved this 
study. Eight- to 12-week-old mice of the C57BL/6J background 
genetically modified to lack the gene for the Na-Cl Co-transporter (NCC) 
(NCC KO) and IL-18KO mice were purchased from The Jackson 
Laboratory (Bar, Harbor, ME). 
b. Study Design 
 
i. Prior to diet intervention, NCCKO male (n=10) mice had free access to 
standard chow and water. After baseline metabolic and cardiac 
assessment, each group was divided so that half of the group (n=5) was 
assigned to maintain a standard chow diet (Teklad LM-485; Envigo) 
while the other half (n=5) was assigned to maintain a “western diet” (WD) 
rich in saturated fat and sugar (Teklad TD.88137; Envigo). A group of 
female mice were studied as well to see differences associated with e 
gender. However, in this study, only the male mice are reported. IL-18 
KO and wild-type (n=10/group) were also fed with WD to be used as 
comparison for the NCCKO mice. The study was performed over an 8 
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to 16 week period to assess metabolic and cardiac phenotype. Nutrient 
composition of each diet is listed in Table 2 below.  
 
 
Figure 14. Research Design. 
 
Dietary composition  
in %kcal 
Standard Diet 
(SD) 
Western Diet 
(WD) 
Carbohydrate 44.3 42.7 
Protein 19.1 15.2 
Total Fat 5.8 42.0 
Saturated Fat %  
of total fatty acids 
0.8 61.8 
Cholesterol -- 0.2 
Kcal/g  
(Energy Density) 
3.1 4.5 
 
Table 2. WD Composition. Nutrient composition of Standard Diet (SD) and Western Diet (WD). 
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c. Food intake and body weight 
 
i. Food intake was measured biweekly as the disappearance of food in 
grams (g) since last observation. Body weight was measured weekly 
using a scale and recorded in grams.  
d. Oral Glucose Tolerance Test (OGTT) 
 
i. Mice were fasted overnight (16 hours) before measurements of fasting 
blood glucose. The mice were transferred from their previous cage to 
clean cages with no evidence of food or feces in the new cage. Mice had 
free access to water during the fasting period. The blood was collected 
from the distal tails of the mice. The first drop of blood removed via 
gauze pad, and the following drop of blood was used to obtain serum 
glucose concentrations with an AimStrip Plus Blood Glucose Meter 
(Ermaine Laboratories Inc.) and AimStrip Plus Blood Glucose Test 
Strips (Ermaine Laboratories Inc.). Blood glucose concentrations were 
measured at baseline after the 16 hours fasting and at time points 15, 
30, 60, and 120 minutes after glucose challenge. A 20% by weight D-
(+)-Glucose (Sigma-Aldrich) solution in water (ex. 2g D-(+)-Glucose in 
10mL water) and mice were carefully given 10µL/g body weight via oral 
gavage. All the NCC KO mice received the test at baseline and before 
the study termination, while the IL-18 KO and wild-type received the test 
only at baseline, and fasting glycemia prior to termination. For 
consistency, the fasting glycemia is reported for all three groups.  
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e. Insulin Tolerance Test (ITT) 
 
i. Mice were fasted for 6 hours before measurements of serum glucose. 
The mice were transferred from their previous cage to clean cages with 
no evidence of food or feces in the new cage. Mice had free access to 
water during the fasting period. Blood was collected from the distal tails 
of the mice, the first drop of blood removed via gauze pad, and the 
following drop of blood was used to obtain serum glucose concentrations 
with an AimStrip Plus Blood Glucose Meter (Ermaine Laboratories Inc.) 
and AimStrip Plus Blood Glucose Test Strips (Ermaine Laboratories 
Inc.). Serum glucose concentrations were measured at baseline after 
the 6 hours fasting and at time points 15, 30, 60, and 120 minutes after 
insulin challenge. Stock Insulin (Lantus, insulin glargine injection, 
provided by Virginia Commonwealth Division of Animal Resources) 
provided was 1 Unit/10µL and the overall administration was to be 1 Unit 
Insulin/1kg body weight of mice. The body weight of mice undergoing 
testing was summed to find the amount of Insulin Units needed (ex. 20 
mice totaling 640g = .64 Units = 6.4µL stock Insulin). Insulin was diluted 
in 0.9% Normal Saline (NS) to make the final solution (ex. 20 mice 
totaling 640g requires 6.4mL final volume. For simplicity, a solution 
containing 10uL stock Insulin within a total 10mL volume with 0.9% NS 
as solvent was made).  Mice were given 10µL/g body weight 
intraperitoneal injection of the Insulin/Saline solution and blood glucose 
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was measured at time points mentioned above. This test was performed 
on NCC mice only, therefore the results are not part of the dissertation.  
f. Echocardiography  
 
i. Mice underwent transthoracic Doppler echocardiography (Vevo770; 
VisualSonic, Toronto, ON, Canada, 30MHz probe) under sedation (30-
50 mgkg-1 pentobarbital) to evaluate systolic and diastolic parameters at 
baseline prior to diet administration, 4, 8, and 16 weeks after the 
beginning of either standard or western diet. B-Mode was used to find 
mid-papillary region of the left ventricle. M-Mode was then used to 
measure left ventricular end-diastolic diameter (LVEDD) and left-
ventricular end systolic diameter (LVESD), then left ventricle fractional 
shortening (LVFS) was calculated [(LVEDD-LVESD)/LVEDD]*100. 
Pulse-Wave Doppler was used to assess isovolumetric contraction time 
(ICT), ejection time (ET), and isovolumetric relaxation time (IRT). 
Myocardial Performance index (MPI), also known as Tei index, an 
assessment of global systolic and diastolic function, was calculated as 
[(ICT+IRT)/ET].  
g. IL-18 ELISA 
 
i. Blood was collected from mice through the inferior vena cava at the time 
of death. Blood was incubated in tubes with heparin (BD, Franklin Lakes, 
NJ) for 15 min and then centrifuged at 2,000 rpm at 4°C for 10 min to 
obtain plasma. Samples were stored at −80°C and subsequently 
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analyzed with a specific ELISA for murine IL-18 (plasma, MBL) 
according to the supplier's instructions to assess the induction of IL-18 
after WD. Absorbance was read with a Bio-Tek plate reader (model 
μQuant, Bio-Tek, Winooski, VT) at 450 nm. Data are expressed in 
picograms per milliliter (pg/mL).  
h. Statistical Analysis 
 
i. For the animal study, because of the low expected variance within the 
groups, values are expressed as mean and SEM. The differences 
between groups were assessed using analysis of variance followed by 
the Student t test for unpaired data to compare the individual groups. 
Microsoft Excel and GraphPad Prism 7 were used for statistical 
analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
Results:  
 
We set out to evaluate paramters of metabolism and cardiac function in three groups of 
mice fed a high-saturated fat diet: Wild-type, IL-18KO, and NCCKO.  
 
WD induces systemic release of active IL-18 
 
 To assess the inflammatory state after WD, we measured plasma IL-18 in 
NCCKO and wild-type mice on WD and compared them to separate C57BL6/J wild-type 
mice that were on standard diet (SD). We observed an statistically significant increase 
in plasma IL-18 after WD in wild-type (183.3pg/mL ±  29.3)  and NCCKO (237.6pg/mL ±  
12.7) mice compared to wild-type mice on SD (79.3pg/mL ±  19.9) (Figure 15).  
 
 
Figure 15. WD Increases circulating IL-18. Plasma IL-18 measured by ELISA in wild-type mice and 
NCCKO mice on WD compared to wild-type mice on SD (n=5-8). Data (in pg/mL) are reported as means 
±  SE (One-Way ANOVA — P-values vs. wild-type mice on standard diet).  
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Body Weight changes over study duration 
 
Plotted in Figure 16 (top), we analyzed absolute body weight (g) at 1 week time 
points over the course of 8 weeks for Wild-type, IL-18KO, and NCCKO male mice.  All 
the mice displayed normal appearance and behaviour. At baseline, IL-18KO mice 
weighed significantly more than NCCKO, but not more than wild-type mice. At the later 
time points, the IL-18KO mice started to weigh signifincantly more than the wild-type 
and maintained a constant difference from the NCCKO (Figure 16, top).   
To evaluate rate of growth on WD relative to initial weight in all mouse strains, we 
calculated percent change from baseline (%) at each week (Figure 16, bottom). In this 
way, we can compare the rate at which the mice gain weight, independent from the 
differences at baseline. We found that the IL18KO and NCCKO gain a significantly 
larger percentage of weight, 46.4 % ± 4.1 and 55.0% ±  2.1 respectively, than the wild-
type mice who gained 21.7% ±  6.8 of initial weight (P<0.05) (Figure 16, bottom).  This 
data suggests that NCCKO mice on WD gain weight to a greater extent than wild-type 
mice that resembles body weight changes observed in IL-18KO mice on WD.  
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Figure 16. Increased Body Weight Gain of IL-18KO and NCCKO mice on WD. Absolute body weight 
gain (top) and percent body weight change from baseline (%) (bottom) comparisons between wild-type, 
IL-18KO, and NCCKO over 8 weeks while on Western Diet (n=5-9). (Two-Way ANOVA — #: P<0.05 
NCCKO vs. Wild-type, ^:P<0.05 IL-18KO vs. Wild-Type, *:P<0.05 IL-18KO vs. NCCKO). Data (in g) are 
reported as mean ±SE.  
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WD induced Type II Diabetic phenotype 
 
 In order to assess metabolic function in the three groups of mice before and after 
WD consumption, fasting glucose levels were taken. At baseline before WD, IL-18KO 
and NCCKO mice had significantly higher fasting plasma glucose levels (93.3 ±  4.4 and 
92.6mg/dL ± 5.6 respectively) compared to wild-type mice (78.1mg/dL ±1.7) (Figure 17 
left, P<0.05). After WD, the fasting plasma glucose was not different between any 
groups (151.9 ± 10.6 vs. 165.4 ± 4.7 vs. 156.4 ± 8.0 mg/dL for IL-18KO, NCCKO, and 
Wild-Type respectively, Figure 17 right).  
 
 
  
 
 
Figure 17. Differences in fasting glycemia before, but not after WD. Fasting blood glucose prior to 
western diet (baseline, left) and after 8 weeks (wild-type, IL-18KO) or 16 weeks of western diet (NCCKO) 
(right) (One-Way ANOVA, P-values vs. Wild-Type). Data (in mg/dL) are reported as mean ±SE, n=3-10. 
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Echocardiographic assessment of systolic, diastolic, and global function 
 
 To evaluate the change in cardiac function in the three groups after WD, we 
chose to evaluate percent (%) change from baseline in Fractional Shortening (FS), 
Isovolumetric Relaxation Time (IRT), and Tei Index. When evaluating FS, NCCKO mice 
had a 14% ± 8 decrease in FS, while IL-18KO and wild-type had a 13% ± 4, and 28% ± 
5 decrease, respectively (Figure 18, top). The percent decrease from baseline was 
significantly less in the IL-18KO group compared to Wild-Type, but not statistically 
different between NCCKO and Wild-Type mice. NCCKO mice after WD had a 
significantly smaller increase (29% ± 16) in IRT compared to wild-type (123% ± 21), 
while the IL-18KO % increase in IRT (67 ± 26) was not statistically significant from wild-
type (Figure 18, middle). The percent change in Tei index, a marker of global function, 
from baseline was significantly preserved in NCCKO and IL-18KO mice (62% ± 21 and 
46 ± 22 increase respectively) compared to the wild-type percent increase from baseline 
(162% ± 23 increase, Figure 18, bottom). Collectively, these echocardiographic 
changes over time indicate that after WD, NCCKO mice exhibited less worsening of 
diastolic and global function compared to wild-type mice that resembled the IL-18KO 
phenotype.  
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Figure 18. Attenuated changes in cardiac function after WD in IL-18KO and NCCKO mice. 
Echocardiographic measurements Fractional Shortening (FS, top), Isovolumetric Relaxation Time (IRT, 
middle), and Tei Index (bottom), percent changes from baseline to after western diet completion (wild-
type and IL-18KO 8 weeks, NCCKO 16 weeks). One-Way ANOVA test to evaluate trend within groups, 
and T-test to evaluate statistical differences between groups: #:P<0.05 vs. Wild-Type. Data (in % change) 
are presented as mean ±SE, n=5-9. 
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Discussion 
 
 The results of the current study show that mice genetically lacking the Na-Cl Co-
transporter have an overlapping phenotype with mice genetically lacking IL-18. IL-18 
has both cardiodepressant activity and prevents weight gain by suppressing appetite. 
NCC is a newly discovered receptor for Interleukin-18, and we hypothesized that it may 
in part mediate the negative effects of IL-18 on cardiac function and the positive effects 
of IL-18 on metabolic function during WD feeding. After establishing that a WD induces 
increased levels of IL-18 in both wild-type and NCCKO mice (Figure 15), we assessed 
metabolic and cardiac phenotypes.  
 To study the role of NCC in metabolism, we used an accepted model of diet-
induced obesity whereby mice are fed with a specific diet for at least 8 weeks to induce 
metabolic and cardiac dysfunction. The high energy density and high percentage of total 
and saturated fat diet used as WD (Western Diet) is advantageous in this basic science 
investigation due to its high relevance to consumption habits in western populations. 
NCCKO mice appear to be smaller than the IL-18KO mice at any weekly interval. 
However, to better evaluate weight gain while on the diet, the weight gain was 
measured and normalized by the initial weight (Figure 16, bottom). Evidently, the rate of 
body weight increases from baseline of the NCCKO mice on WD (55% at 8 weeks) has 
striking resemblance to the rate of body weight increase of IL-18KO mice on WD 
(46.4% at 8 weeks) where both groups gained significantly more weight relative to 
baseline than wild-type mice on WD (21.7% at 8 weeks). This is of importance when 
compared to available literature that has investigated body weight gain of IL-18RαKO 
mice. Two groups have observed a pattern whereby the IL-18RαKO mice growth rate 
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on a WD is slower than that of IL-18KO and more closely resembles that of a wild-type 
mouse on WD (Figure 10, Introduction) (102,104). The trend of acute onset and sustained 
obesity while on WD in mice lacking IL-18 or an upstream activator such as NLRP1 or 
TLR4 is well-documented in the literature (98,99,104,108).  
Our observations indicate that perhaps during a state of high-saturated fat 
feeding which induces a low-grade pro-inflammatory state, IL-18 may be signaling in the 
brain to control appetite and in the heart to regulate relaxation to a greater degree 
through NCC rather than the IL-18Rα. Support for IL-18 “favoritism” to NCC has been 
observed in vitro. Conjugated IL-18 showed a higher binding affinity to NCC than to IL-
18Rα [NCC dissociation constant (a concentration that indicates when 50% of binding 
has occurred) Kd = 17.3nM vs. IL-18Rα Kd= 46nM] (51,105).  Additionally, IL-18 has been 
shown to increase peritoneal macrophage NCC mRNA levels by 65 fold, as well as 
increase plasma membrane NCC in macrophages and T-cells treated with IL-18, 
observable by immunostaining (105). It is possible, but has not been analyzed to our 
knowledge, that IL-18 may cause a similar increase in NCC within neural tissue that 
becomes primarily responsible for binding to IL-18 and modifying neural circuits to 
decrease satiety and eventual body weight. 
Importantly, this hypothesis would necessitate careful investigation of food 
intake. A common method of measuring food intake is to measure the disappearance of 
food from the mice cages; however, this measurement has high variability due to the 
fact that mice “play with” the sticky texture of the high-saturated fat diet and do not 
necessarily ingest all of the WD that disappeared from the previous measurement. This 
method was attempted with these groups of mice, but the pitfall of the measurement 
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tool limited the accuracy of the data. A more precise method of measuring food intake 
using a metabolic chamber is in planning to best evaluate physiologic changes in food 
intake in similar groups studied here. 
It cannot be understated that a key component of IL-18 signaling in positively 
affecting metabolism is within the central nervous system (CNS) to decrease appetite 
and food intake. Common to pro-inflammatory states of non-specific illness is the loss of 
appetite(109). Interleukin-18 has been identified in the mouse to contribute to this 
phenomenon. Through a pre-synaptic disinhibitory mechanism, IL-18 disrupts the 
balance of excitatory and inhibitory electrical signals in the amygdala that culminates in 
increased lateral hypothalamic (LH) firing and a decrease in food intake (101). An 
observed reduction in standard diet food intake after central IL-18 administration was 
deemed to be dependent on the presence of the IL-18Rα as brain slices from IL-
18RαKO mice treated with rIL-18 did not exhibit significant changes in electrical 
properties changes as seen in brain slices from IL-18Rα+/+ mice. However, these 
experiments were done in IL-18RαKO mice 3-5 months of age on a standard diet. Mice 
on a standard diet have been shown to have significantly less (approximately 30%) 
plasma IL-18 than mice fed a WD for 8 weeks (86). Additionally, the ELISA results 
shown here indicate circulating IL-18 approximately doubles after WD (Figure 14). It is 
possible the IL-18Rα+/+ and IL-18RαKO mice fed standard diet, and studied specifically 
for IL-18/IL-18Rα mediated hypophagia, did not have sufficiently elevated IL-18 levels to 
induce relevant NCC expression within the amygdala and hypothalamus, therefore NCC 
function as a receptor could not have been evaluated in that setting.  
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Additionally, our analysis of the obese phenotype through weight gain is not as 
holistic as appears in other literature that separates body composition by fat mass and 
fat-free mass with the use of sophisticated tools such as dual energy X-ray 
absorptiometry (DEXA) or EchoMRI. A possible relevancy of accurately measuring body 
mass composition to the NCCKO mice here is a finding of increased bone mineral 
density (BMD) in NCCKO mice compared to NCC+/+ mice. However, despite an 
increased BMD, the absolute weight of littermate NCC-/- and NCC+/+ mice was indifferent 
(25.7g vs. 25.9g respectively) (110). More specific tools, while more expensive, could 
have elucidated more intricacies of fat and lean mass within the obese phenotypes 
observed.   
To assess whole body glucose metabolism we measured overnight fasting 
plasma glucose levels before and after WD. Prior to the start of WD the IL-18KO and 
NCCKO mice had significantly higher fasting glucose (93.3 and 92.6mg/dL respectively) 
compared to wild-type mice (78.1mg/dL) (Figure 17, left). Although these levels are still 
within a normal range, they indicate that IL-18 and NCC are directly or indirectly 
important for glucose homeostasis. Similar observations have been identified for IL-
18KO mice where, by 3 months of age IL-18KO mice have elevated fasting insulin and 
decreased tolerance to glucose and by 6 months of age exhibit full-fledged Type II 
Diabetes characterized by elevated fasting glucose, decreased glucose tolerance, and 
decreased insulin sensitivity (96).  
Peripheral homeostatic functions of IL-18 that relate to energy metabolism are 
not well understood. In patients, elevated plasma IL-18 are positively associated with 
BMI, Type II Diabetes (T2D), and waist-to-hip ratios, and negatively correlated with 
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insulin sensitivity (93 111). This could reflect another phenomenon seen in obese patients 
of IL-18 resistance. Leukocytes isolated from obese or T2D patients have a blunted 
production of INF-γ in response to IL-18 stimulation that was accompanied by a 50% 
reduction in plasma membrane Il-18Rα and IL-18Rβ (112). Interestingly though, 
intraperitoneal recombinant IL-18 was able to improve insulin sensitivity in IL-18+/+ and 
IL-18-/- mice (96). Additionally, in vitro and ex vivo studies have shown that exogenous 
IL-18 treatment increases AMPK and fat oxidation (102). AMPK is an intracellular protein 
that coordinates a multitude of cellular functions, including fatty acid uptake, β-oxidation, 
translocation of GLUT-4 vesicles to the plasma membrane, promotion of glycolysis and 
inhibition of gluconeogenesis, providing further support for IL-18 acting in part to 
improve glucose metabolism (113).  
 Although no other basic science studies to our knowledge have investigated the 
effects of NCCKO on glucose metabolism, two potential clinical correlations can be 
made. A possible link that has been made for the development of glucose intolerance 
and insulin resistance in patients with genetic mutations in NCC, clinically named 
Gitelman Syndrome, or hypokalemia in patients receiving thiazide diuretics 
(hydrochlorothiazide, chlorthalidone: NCC blockers). Gitelman Syndrome patients and 
patients on thiazide diuretics may exhibit hypokalemia owing to increased urinary K+ 
excretion in the distal tubule and collecting duct (114). Thiazide-induced dysglycemia is a 
well-observed phenomenon, but the mechanism behind it is unclear. Speculation to this 
point focuses on K+ mediated release of insulin by pancreatic β-cells, but it is not 
established as to whether small decreases in K+ are physiologically relevant to cause a 
decrease in insulin secretion that results in hyperglycemia (115).  
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Connecting apparent findings of IL-18 improving insulin sensitivity, and NCC 
acting as a receptor for IL-18 binding and effects, it is possible that IL-18 functions 
through NCC to improve insulin sensitivity, although this requires much further 
investigation. Although we see higher fasting plasma glucose at baseline in the NCCKO 
and IL-18KO compared to wild-type, WD over time does not worsen glycemia, indicating 
glucose metabolism during high-fat diet may be independent of IL-18 and NCC function 
(Figure 17, right). This finding is somewhat dissociated from the severity of obesity 
development. Despite gaining significantly more weight than wild-type, NCCKO and IL-
18KO display similar fasting glycemia. Future investigation into glucose metabolism and 
insulin function is of interest in the NCCKO genotype to perhaps investigate 
contributions of electrolyte abnormalities and/or IL-18 mediated effects to alterations in 
glucose metabolism.  
To evaluate the contribution of NCC to cardiac function during WD, we assessed 
systolic, diastolic, and global function parameters via echocardiography. We report 
percent change in cardiac function of groups to normalize for baseline differences and 
specifically evaluate the effect of the WD on changes in cardiac function. For all three 
groups there was decline in fractional shortening (FS) with only the IL-18KO group 
having less worse FS changes after WD compared to wild-type mice (13% vs 28% 
decline respectively) (Figure 18, top), indicating systolic function was not statistically 
preserved by genetic deletion of NCC after WD. This result was somewhat expected as 
the model of diet induced obesity induces mild systolic dysfunction, but may retain an 
ejection fraction that is still considered preserved.  
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Pulse wave Doppler measurements allowed for analysis of diastolic and global 
function, specifically isovolumetric relaxation time (IRT) and Tei Index (or Myocardial 
Performance Index). For orientation, an increase in IRT or Tei Index indicates 
worsening function. In terms of changes in the early relaxation of the left ventricle after 
WD, NCCKO mice had significantly attenuated percent changes from baseline 
compared to Wild-Type (29% vs. 123%), whereas the IL-18KO percent change from 
baseline was not significantly less than the Wild-Type (67% vs. 123%) (Figure 18, 
middle). Further support for a less severe effect of WD on cardiac function for NCCKO 
mice is supported by a statistically lower percent increase from baseline in global 
evaluation via the Tei Index. After WD, both the IL-18KO and NCCKO mice had 
significantly lower percent increases in Tei Index (46% and 62% increase respectively) 
compared to wild-type mice (162% increase), indicating that the WD had less of a 
cardiodepressant effect in the IL-18KO and NCCKO groups (Figure 18, bottom). 
Collectively, the echocardiographic results indicated that IL-18 induced by WD may 
have a greater impact on diastolic function, and the genetic knockout of IL-18 or the 
NCC receptor for IL-18 resulted in less worsened diastolic dysfunction from baseline 
after WD.  
Keeping in mind clinical heart failure relevancies, a large clinical study evaluating 
efficacy of differing anti-hypertensive pharmacotherapy in high-risk hypertensive 
patients discovered that the use of a NCC blocker, Chlorthalidone, significantly reduced 
the risk of heart failure at 4-8 year follow up compared to an ACE inhibitor (Lisinopril) or 
a Calcium-Channel Blocker (Amlodipine) (107). This finding represents a possible link to 
the research investigated here, whereby inhibition of NCC aside from the primary goal 
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of diuresis to control blood pressure may also be provide direct inhibition of IL-18 
signaling in the myocardium to prevent or slow the progression of cardiac dysfunction. 
This line of thinking is of high interest that we aim to investigate further in the future.  
An alternative method to evaluate novel contributions of NCC to IL-18 signaling 
could have been through the use of pharmacologic inhibitors of the ion transporter that 
are commercially available, notably hydrochlorothiazide (HCTZ). A flaw to this design 
are reports that HCTZ does not cross the blood brain barrier and therefore centrally 
mediated effects of NCC may not be able to be assessed; however, this could have 
been acutely overcome with direct intracerebral administration of HCTZ via cannulas 
placed into the skull and brain (120). This direct central administration method is 
complicated; however, by post-surgical induction of pain, distress, and risk for infection 
(121). Additionally, although the genetic knockout of NCC has yet to result in embryonic 
lethality to our knowledge, NCC has important other physiologic contributions. As noted 
prior, the Na-Cl Co-transporter is partially responsible for electrolyte homeostasis, 
particularly K+, Mg2+. Therefore, a temporally controlled inducible mutation of SLC12a3, 
the gene encoding NCC, in mice could prove to be a beneficial model to study the 
physiology related to NCC in the future.  
A separate limitation of this study is the fact that the wild-type mice are not 
littermates to the NCCKO or IL-18KO mice. Although all of the mice studied have the 
same C57Bl6/J background, this is of great importance when attempting to control for a 
single genetic change and we cannot exclude the effects of other compounding genetic 
alterations when assessing the data. Moreover, genetic knockout mice remain inbred, 
which can lead to reduced biological fitness of the population.  
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 The strength of research presented here derives from the novel findings, 
specifically regarding the possible role of the Na-Cl Co-transporter (NCC) in mediating 
IL-18 effects on metabolic and cardiac function. We believe the investigation and results 
here have laid a foundation for a more elaborate research plan designed to 
comprehensively investigate the known components of IL-18 signaling in a similar 
experimental model. Others have described that protection from the pro-inflammatory 
disease of atherosclerosis is observed only after combined genetic knockout of IL-18R 
and NCC (IL-18Rα-/-NCC-/-), and not singular littermate knockouts of either (IL-18R-/- or 
NCC-/-) (105). Although the data presented here investigates the sole knockout of NCC, 
in the future we hope to replicate the double knockout design and further investigate IL-
18 signaling mechanisms in the context of diet-induced obesity. In order to accomplish 
this, crossbreeding to obtain littermates with differing components of the IL-18 signaling 
system missing must be done. Crossbreeding and genomic analysis is currently 
underway to establish these mouse lines in preparation for future studies.  
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